Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06480565 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Trial of ADI-270 in ccRCC

A Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Adicet Therapeutics.

Active
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT06480565 is a Phase 1 study of Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Adicet Therapeutics. The registered enrollment target is 60 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06480565, a Phase 1 study of Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Adicet Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.

Conditions Studied

Clear Cell Renal Cell Carcinoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG ADI-270

Study Locations (1)

California

  • Adicet Clinical Trials - Redwood City

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-12-12
Est. Completion 2027-06
Phase Phase 1

Sponsor

Adicet Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06480565

The ClinicalTrials.gov registry entry for NCT06480565 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (70% lower). The listed sponsor is Adicet Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT06480565 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06480565 about?

NCT06480565 is a clinical study titled "A Phase 1/2 Trial of ADI-270 in ccRCC". This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.

What is the current status of trial NCT06480565?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-12-12. Estimated completion is 2027-06.

What conditions does trial NCT06480565 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.

What interventions are being tested in trial NCT06480565?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ADI-270 (DRUG).

Who is sponsoring clinical trial NCT06480565?

This trial is sponsored by Adicet Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06480565 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.